Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2012 1
2013 3
2014 2
2015 3
2016 2
2017 2
2018 1
2019 10
2020 6
2021 7
2022 2
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Splenic irradiation for splenomegaly: A systematic review.
Zaorsky NG, Williams GR, Barta SK, Esnaola NF, Kropf PL, Hayes SB, Meyer JE. Zaorsky NG, et al. Cancer Treat Rev. 2017 Feb;53:47-52. doi: 10.1016/j.ctrv.2016.11.016. Epub 2016 Dec 22. Cancer Treat Rev. 2017. PMID: 28063304 Free PMC article. Review.
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review.
Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ. Appeldoorn TYJ, et al. Clin Pharmacokinet. 2023 Apr;62(4):559-571. doi: 10.1007/s40262-023-01225-7. Epub 2023 Mar 31. Clin Pharmacokinet. 2023. PMID: 37000342 Free PMC article.
BACKGROUND AND OBJECTIVE: Ruxolitinib is a tyrosine kinase inhibitor targeting the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. Ruxolitinib is used to treat myelofibrosis, polycythemia vera and steroid-refractory graft-versus-hos …
BACKGROUND AND OBJECTIVE: Ruxolitinib is a tyrosine kinase inhibitor targeting the Janus kinase (JAK) and signal transducer and activator of …
Extramedullary hemopoiesis.
Orphanidou-Vlachou E, Tziakouri-Shiakalli C, Georgiades CS. Orphanidou-Vlachou E, et al. Semin Ultrasound CT MR. 2014 Jun;35(3):255-62. doi: 10.1053/j.sult.2013.12.001. Epub 2013 Dec 19. Semin Ultrasound CT MR. 2014. PMID: 24929265 Review.
Various chronic hematologic disorders that lead to ineffective hemopoiesis or inadequate bone marrow function (ie, chronic hemolytic anemias, thalassemia, sickle cell anemia, myelofibrosis of many causes, lymphoma, and leukemia) can potentially precipitate extramarrow new …
Various chronic hematologic disorders that lead to ineffective hemopoiesis or inadequate bone marrow function (ie, chronic hemolytic anemias …
Management of Myeloproliferative Neoplasms (MPNs).
Nurgat Z, Lawrence M. Nurgat Z, et al. J Oncol Pharm Pract. 2022 Sep;28(6):1400-1410. doi: 10.1177/10781552221082293. Epub 2022 Mar 16. J Oncol Pharm Pract. 2022. PMID: 35296179
Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis.
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, Stahl M. Bewersdorf JP, et al. Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e712-e723. doi: 10.1016/j.clml.2020.05.018. Epub 2020 May 28. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32669244 Free PMC article.
BACKGROUND: Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm characterized by progressive bone marrow failure, increased risk of progression to acute myeloid leukemia, and constitutional symptoms. ...
BACKGROUND: Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm characterized by progressive bone ma …
Myelofibrosis: best practices, controversies and 2019 update.
Cruz NM, Gergis U, Silver RT. Cruz NM, et al. Expert Rev Hematol. 2020 Jan;13(1):71-84. doi: 10.1080/17474086.2020.1691519. Epub 2019 Nov 30. Expert Rev Hematol. 2020. PMID: 31709843
Introduction: Recent advances in the prognostic scheme and treatment of primary and secondary myelofibrosis (MF) have resulted in an overwhelming amount of clinical information to assimilate. ...The authors conducted a systematic literature review to answer questions regar …
Introduction: Recent advances in the prognostic scheme and treatment of primary and secondary myelofibrosis (MF) have resulted in an …
Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Sureau L, Orvain C, Ianotto JC, Ugo V, Kiladjian JJ, Luque Paz D, Riou J. Sureau L, et al. Blood Cancer J. 2021 Jul 27;11(7):135. doi: 10.1038/s41408-021-00526-z. Blood Cancer J. 2021. PMID: 34315858 Free PMC article.
Myelofibrosis is a myeloproliferative neoplasm associated with constitutional symptoms, increasing splenomegaly, and worsening cytopenias. Janus kinase (JAK) inhibitors have been used for the treatment of myelofibrosis for several years, but there is a lack of compa …
Myelofibrosis is a myeloproliferative neoplasm associated with constitutional symptoms, increasing splenomegaly, and worsening cytope …
How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ, Duncombe AS, McMullin MF, O'Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA. Titmarsh GJ, et al. Am J Hematol. 2014 Jun;89(6):581-7. doi: 10.1002/ajh.23690. Am J Hematol. 2014. PMID: 24971434 Free article. Review.
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and preval …
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), …
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data.
Bosi A, Barcellini W, Passamonti F, Fattizzo B. Bosi A, et al. Blood Rev. 2023 Nov;62:101132. doi: 10.1016/j.blre.2023.101132. Epub 2023 Sep 9. Blood Rev. 2023. PMID: 37709654 Free article. Review.
Forty-six studies, mainly retrospective with various androgen types and doses, were included: 12 on acquired aplastic anemia (AA), 11 on inherited BMF, 17 on myelodysplastic syndromes (MDS), and 7 on myelofibrosis. Responses ranged from 50 to 70% in inherited BMF, 40-50% i …
Forty-six studies, mainly retrospective with various androgen types and doses, were included: 12 on acquired aplastic anemia (AA), 11 on inh …
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.
Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Bewersdorf JP, et al. Transplant Cell Ther. 2021 Oct;27(10):873.e1-873.e13. doi: 10.1016/j.jtct.2021.05.016. Epub 2021 May 28. Transplant Cell Ther. 2021. PMID: 34052505 Free PMC article.
Allogeneic hematopoietic cell transplant (allo-HCT) remains the only potentially curative therapeutic modality for patients with primary or secondary myelofibrosis (MF). However, many patients are considered ineligible for allo-HCT, and transplant-related mortality can be …
Allogeneic hematopoietic cell transplant (allo-HCT) remains the only potentially curative therapeutic modality for patients with primary or …
39 results